Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27758856
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Biol+Chem
2016 ; 291
(48
): 25096-25105
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Novel Antibody for the Treatment of Transthyretin Amyloidosis
#MMPMID27758856
Hosoi A
; Su Y
; Torikai M
; Jono H
; Ishikawa D
; Soejima K
; Higuchi H
; Guo J
; Ueda M
; Suenaga G
; Motokawa H
; Ikeda T
; Senju S
; Nakashima T
; Ando Y
J Biol Chem
2016[Nov]; 291
(48
): 25096-25105
PMID27758856
show ga
Familial amyloidotic polyneuropathy (FAP) is a systemic amyloidosis mainly caused
by amyloidogenic transthyretin (ATTR). This incurable disease causes death ?10
years after onset. Although it has been widely accepted that conformational
change of the monomeric form of transthyretin (TTR) is very important for amyloid
formation and deposition in the organs, no effective therapy targeting this step
is available. In this study, we generated a mouse monoclonal antibody, T24, that
recognized the cryptic epitope of conformationally changed TTR. T24 inhibited TTR
accumulation in FAP model rats, which expressed human ATTR V30M in various
tissues and exhibited non-fibrillar deposits of ATTR in the gastrointestinal
tracts. Additionally, humanized T24 (RT24) inhibited TTR fibrillation and
promoted macrophage phagocytosis of aggregated TTR. This antibody did not
recognize normal serum TTR functioning properly in the blood. These results
demonstrate that RT24 would be an effective novel therapeutic antibody for FAP.